Skip to content

Thermo Fisher Scientific TMO Long-term debt, gross

Long-term debt, gross at other companies

Revvity logo
RevvityRVTY
BioLife Solutions logo
BioLife SolutionsBLFS
IQVIA logo
IQVIAIQV

Other financials

Income statement

See full
Revenue$11.0B+6.2%
Operating income$1.9B+8.6%
Net income$1.7B+9.6%
EPS (diluted)$4.43+11.3%

Balance sheet

See full
Cash & equivalents$3.3B-21.4%
Total debt$43.2B+16.6%
Total equity$51.9B+5.2%
Total assets$113.28B+14.4%

Cash flow

See full
Operating cash flow$1.2B+64.9%
CapEx$376.0M+3.9%
Free cash flow$816.0M+126%

Valuation

See full
Market cap$186.32B+25.0%
Enterprise value$226.2B+24.4%
P/E27.2×+4.6×
P/S4.3×-0.8×

Profitability

See full
Gross margin58.3%
Operating margin17.2%+0.8pp
Net margin15.2%+1.0pp
FCF margin15.7%-2.1pp

Returns & leverage

See full
Return on equity13.5%-0.2pp
Debt / equity0.8×+0.1×
Current ratio1.5×-0.2×

Where this comes from

Reported directly by Thermo Fisher Scientific in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentCarryingAmount.

The official record: Thermo Fisher Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Thermo Fisher Scientific's long-term debt, gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Thermo Fisher Scientific's long-term debt, gross?
Thermo Fisher Scientific (TMO) reported long-term debt, gross of $43.27B in Q1 2026.
How has Thermo Fisher Scientific's long-term debt, gross changed year-over-year?
Thermo Fisher Scientific's long-term debt, gross increased by 26.3% year-over-year, from $34.26B to $43.27B.
What is the long-term trend for Thermo Fisher Scientific's long-term debt, gross?
Over 5 years (2020 to 2025), Thermo Fisher Scientific's long-term debt, gross has grown at a 12.5% compound annual growth rate (CAGR), from $21.92B to $39.46B.